Khulood Majid Alsaraf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khulood Majid Alsaraf has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Raghad Abdulsalam Khaleel
Al Iraqia University
2 shared publications - Saja Majeed Shareef
Department of Pharmacology and Toxicology, College of Pharmacy, Al-Esraa University, Baghdad, Iraq
2 shared publications - Maadh Fawzi Nassar
University Putra Malaysia
1 shared publication - Maiss Saadi1 shared publication
- Marwan Mahtook1 shared publication
- Noor Mohammed Obaid
College of Pharmacy, Al-Esraa University, Baghdad , Iraq
1 shared publication
Latest Publications
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 141-144
Real-world data on the effectiveness of the meloxicam and pridinol combination for musculoskeletal pain
Musculoskeletal pain includes several types of discomfort associated with the skeletal system. Pharmaceutically, pridinol was developed in order to relax muscles. No empirical data exist to support the effectiveness of using meloxicam in combination therapy for the treatment of musculoskeletal pain. This study compared pridinol and meloxicam for musculoskeletal pain. The current observational study assessed a total of 82 patients. The study’s participants were divided into three groups: the “meloxicam” group, the “pridinol” group, and the “meloxicam + pridinol” group. Pain levels were measured before and four weeks after giving the drug, by using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We employed a Kruskal-Wallis test in order to evaluate the variations in pain measurement among the groups. The three groups’ VAS and WOMAC scores did not differ before the drug administration. The “meloxicam + pridinol” treatment resulted in significant pain relief based on VAS and WOMAC scores at 1, 2, and 4 weeks (as compared to other groups; p<0.05). At 4 weeks, the VAS and WOMAC ratings exhibited no significant pain relief in the “meloxicam” group when compared to the “pridinol” group. The meloxicam-pridinol combination proved efficacious for musculoskeletal pain, and is recom¬mended for its therapy.
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 141-144
Real-world data on the effectiveness of the meloxicam and pridinol combination for musculoskeletal pain
Musculoskeletal pain includes several types of discomfort associated with the skeletal system. Pharmaceutically, pridinol was developed in order to relax muscles. No empirical data exist to support the effectiveness of using meloxicam in combination therapy for the treatment of musculoskeletal pain. This study compared pridinol and meloxicam for musculoskeletal pain. The current observational study assessed a total of 82 patients. The study’s participants were divided into three groups: the “meloxicam” group, the “pridinol” group, and the “meloxicam + pridinol” group. Pain levels were measured before and four weeks after giving the drug, by using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We employed a Kruskal-Wallis test in order to evaluate the variations in pain measurement among the groups. The three groups’ VAS and WOMAC scores did not differ before the drug administration. The “meloxicam + pridinol” treatment resulted in significant pain relief based on VAS and WOMAC scores at 1, 2, and 4 weeks (as compared to other groups; p<0.05). At 4 weeks, the VAS and WOMAC ratings exhibited no significant pain relief in the “meloxicam” group when compared to the “pridinol” group. The meloxicam-pridinol combination proved efficacious for musculoskeletal pain, and is recom¬mended for its therapy.
- Open Access
- 29 October 2021
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 5(33),p. 79-88
The effect of fluoxetine and imipramine on the improvement of depressive-like behaviors and HPA axis (hypothalamic-pituitary-adrenal cortex) activity – an animal model
Depression is one of the most common mental disorders and numerous medications are used to reduce the psychotic symptoms. The aim of this study was to evaluate the therapeutic effects of two commonly used antidepressant drugs, including Fluoxetine (Flx) and Imipramine (IMP) to improve depressive-like behaviors as well as the activity of hypothalamic pituitary-adrenal cortex (HPA). Methods: Initially, 40 adult male albino rats weighing 25±5g were selected for this experimental study. The animals were kept or housed in separate cages under standard temperature (25±1°C) and light-dark conditions (12 hours light/dark cycle). Rats were divided into four groups: each group containing 10 rats, control, immobility stress, Flx receiver, and IMP receiver. Polyethylene restrainer was used to induce immobility stress for 14 days. Finally, the parameters of IMT, ST, serum levels of corticosterone and glucose were evaluated in all four mentioned groups. Results: The results showed that the patient group's immobility time (IMT) increased compared to the control group, but the patient group's swimming time (ST) decreased compared to the control group. The effect of immobility stress on IMT, ST, corticosterone, and glucose factors in the patient group was increasing and decreasing, respectively, whereas the effect of Flx drug on these mentioned factors was decreasing, increasing and respectively, while the effect of IMP on all mentioned factors was decreasing and increasing, respectively. Conclusion: Based on the results, it can be concluded that the antidepressant Flx and IMP drugs have various effects on the HPA activity, and the application of immobility stress causes depressive-behavior. Moreover, Flx is more effective than IMP in the treatment of depressive behaviors
- 29 October 2021
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 5(33),p. 79-88
Open AccessThe effect of fluoxetine and imipramine on the improvement of depressive-like behaviors and HPA axis (hypothalamic-pituitary-adrenal cortex) activity – an animal model
Depression is one of the most common mental disorders and numerous medications are used to reduce the psychotic symptoms. The aim of this study was to evaluate the therapeutic effects of two commonly used antidepressant drugs, including Fluoxetine (Flx) and Imipramine (IMP) to improve depressive-like behaviors as well as the activity of hypothalamic pituitary-adrenal cortex (HPA). Methods: Initially, 40 adult male albino rats weighing 25±5g were selected for this experimental study. The animals were kept or housed in separate cages under standard temperature (25±1°C) and light-dark conditions (12 hours light/dark cycle). Rats were divided into four groups: each group containing 10 rats, control, immobility stress, Flx receiver, and IMP receiver. Polyethylene restrainer was used to induce immobility stress for 14 days. Finally, the parameters of IMT, ST, serum levels of corticosterone and glucose were evaluated in all four mentioned groups. Results: The results showed that the patient group's immobility time (IMT) increased compared to the control group, but the patient group's swimming time (ST) decreased compared to the control group. The effect of immobility stress on IMT, ST, corticosterone, and glucose factors in the patient group was increasing and decreasing, respectively, whereas the effect of Flx drug on these mentioned factors was decreasing, increasing and respectively, while the effect of IMP on all mentioned factors was decreasing and increasing, respectively. Conclusion: Based on the results, it can be concluded that the antidepressant Flx and IMP drugs have various effects on the HPA activity, and the application of immobility stress causes depressive-behavior. Moreover, Flx is more effective than IMP in the treatment of depressive behaviors
- Open Access
- 31 August 2021
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 4(32),p. 78-86
The protective effect of Zingiber officinale L. extract on kidney tissues and blood factors of kidney functions after the damage caused by Azathioprine
The most commonly prescribed medication for autoimmune disorders is Azathioprine (AZA), which negatively affects renal function and tissue structure. The aim of this work was to measure the therapeutic impact of Zingiber officinale L. extract (ZOE) on improving the function and structure of AZA-induced renal damaged tissue. Methods: 70 rats with a weight range of 200±10 g and an age of 95±5 days were chosen for this experimental study. The animals were grouped into seven groups of ten, with two groups receiving no treatment (control groups) and five groups receiving ZOE, AZA, “AZA + ZOE”, and normal saline. AZA was given intraperitoneally, and ZOE was given by gavage (i.e., nasogastric tube) for 21 days. Finally, urea, uric acid, creatinine parameters, and the diameter of some key or important parts of the kidney were measured in different animal groups. Results: it was found that the use of AZA (50 mg/kg) increased serum urea and creatinine concentrations, blood uric acid in comparison to the group of control (P<0.05). Whereas injecting ZOE (200 mg/kg) induces a considerable decrease in the concentration of the compounds mentioned above as compared to control animals and animals given AZA (P<0.05). Furthermore, the findings revealed that AZA caused inflammation and kidney tissue destruction, while ZOE improved, restored, and recovered the affected kidney tissue. Conclusion: according to the research findings, it can be decided that ZOE has a protective and therapeutic impact on kidney tissue owing to its strong antioxidant attributes and its ability to inhibit free radicals produced by azathioprine
- 31 August 2021
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 4(32),p. 78-86
Open AccessThe protective effect of Zingiber officinale L. extract on kidney tissues and blood factors of kidney functions after the damage caused by Azathioprine
The most commonly prescribed medication for autoimmune disorders is Azathioprine (AZA), which negatively affects renal function and tissue structure. The aim of this work was to measure the therapeutic impact of Zingiber officinale L. extract (ZOE) on improving the function and structure of AZA-induced renal damaged tissue. Methods: 70 rats with a weight range of 200±10 g and an age of 95±5 days were chosen for this experimental study. The animals were grouped into seven groups of ten, with two groups receiving no treatment (control groups) and five groups receiving ZOE, AZA, “AZA + ZOE”, and normal saline. AZA was given intraperitoneally, and ZOE was given by gavage (i.e., nasogastric tube) for 21 days. Finally, urea, uric acid, creatinine parameters, and the diameter of some key or important parts of the kidney were measured in different animal groups. Results: it was found that the use of AZA (50 mg/kg) increased serum urea and creatinine concentrations, blood uric acid in comparison to the group of control (P<0.05). Whereas injecting ZOE (200 mg/kg) induces a considerable decrease in the concentration of the compounds mentioned above as compared to control animals and animals given AZA (P<0.05). Furthermore, the findings revealed that AZA caused inflammation and kidney tissue destruction, while ZOE improved, restored, and recovered the affected kidney tissue. Conclusion: according to the research findings, it can be decided that ZOE has a protective and therapeutic impact on kidney tissue owing to its strong antioxidant attributes and its ability to inhibit free radicals produced by azathioprine